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The  aim of this study  was to identify  predictors  of 30-day and  midterm  mortality  after 
transcatheter aortic valve implantation (TAVI) by means of a systemic review. TAVI was 
demonstrated to be safe and efficacious in patients with severe aortic stenosis. An accurate 
estimation of procedural  risk of these patients represents an actual challenge. The PubMed 
and Cochrane  Collaboration  databases  were systematically  searched  for studies reporting 
on the incidence and  independent predictors  of 30-day and  midterm  mortality.  Adverse 
events were pooled with random  effect, whereas  independent  predictors  are  reported  as 
odds ratios  (ORs) with 95% confidence  intervals  (CIs). A total  of 25 studies  with 8,874 
patients  were included (median  age 82.5 – 1.5 years, 54.6% women). At 30 days, 7.5% of 
patients (n [ 663) died. At midterm follow-up (median 365 days, interquartile  range 267 to 
365 days), the cumulative mortality rate was 21.6% (n [ 1,917). Acute kidney injury (AKI) 
stage ‡2 (OR 18.0, 95% CI 6.3 to 52), preprocedural hospitalization  for heart  failure (OR 
9.4, 95% CI 2.6 to 35), periprocedural acute myocardial  infarction  (OR 8.5, 95% CI 2.6 to 
33.5), and increased proebrain natriuretic  peptide (pro-BNP) levels (OR 5.4, 95% CI 1.7 to 
16.5) were the most important  independent  predictors  of 30-day mortality.  Increased  pro- 
BNP levels (OR 11, 95% CI  1.5 to 81), AKI stage  3 (OR 6.8, 95% CI  2.6 to 15.7), left 
ventricular  ejection fraction <30% (OR 6.7, 95% CI 3.5 to 12.7), and periprocedural acute 
myocardial  infarction  (OR 6.5, 95% CI 2.3 to 18.1) represented  the predictors  of midterm 
mortality. In conclusion, in this large meta-analysis of patients undergoing TAVI, we found 
that  high  pro-BNP  levels and  postprocedural AKI  were the  strongest  independent pre- 
dictors  of both  30-day  and  1-year  mortality.  These  findings  may  contribute  to a  better 
understanding  of  the  risk  assessment  process  of  patients  undergoing  TAVI.         2014 





























42             Despite  being  one  of  the  most  important aspects  of 
43        transcatheter  aortic  valve  implantation  (TAVI)  practice, 
44        adequate patient selection represents a  clinical issue not 
45        fully  resolved.  Allocating  transcatheter treatment  to  the 
46        correct patients, reasonably expected to benefit in terms of 
47        functionality and survival, is essential to avoid unnecessary 
48 
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high-risk procedures with accompanying costs.
1e4  
Howev- 
er, assessment of patient eligibility is often complex because 
of the extensive co-morbidity encountered in candidates for 
TAVI, rendering it difficult to estimate whether a beneficial 
treatment  effect  can  be  expected  in  individual patients, 
especially because surgical risk scores (EuroSCORE and 
 
 
Cardiovascular Center, Bern University Hospital, Bern, Switzerland; 
mDepartment of Cardiology, Centre Marie Lannelongue, Le Plessis-Rob- 
inson,  France; nCardiology, Beilinson Hospital, Rabin Medical Center, 
Petach-Tikva, Israel; oTel-Aviv University, Sackler Faculty of Medicine, 
Tel-Aviv, Israel; pDepartment of Cardiology and Cardio-Thoracic Surgery, 
Academic Medical CentereUniversity  of  Amsterdam, Amsterdam, The 
Netherlands; and  qInterventional  Cardiology Unit,  EMO-GVM Centro 
Cuore Columbus, Milan, Italy. Manuscript received April 25, 2014; revised 
manuscript received and accepted July 30, 2014. 
See page 7 for disclosure information. 
*Corresponding      author:      Tel:      (þ39)       0116335570;      fax: 
(þ39) 0116336769. 






















0002-9149/14/$ - see front matter     2014 Elsevier Inc. All rights reserved.                                                                                                  www.ajconline.org 
http://dx.doi.org/10.1016/j.amjcard.2014.07.081
REV 5.2.0 DTD      AJC20643_proof      29 August 2014      4:30 pm      ce  
 
 





























































































Society of Thoracic Surgery score) are less reliable in 
patients undergoing TAVI.
5e7   
The  primary challenge to 
improve patient selection and counseling is hindered by the 
search for accurate and validated risk factors for mortality 
“transcatheter aortic”) AND (“adverse events” OR “30 days 
events” OR “mid-term prognosis”) AND english[lang] AND 


































yield helpful tools that could facilitate decision making of 
the  heart  team.  Contemporary  literature  falls  short  in 
addressing this issue, despite the availability of numerous 
publications, as the knowledge on predictors of mortality is 
fragmentary. Meta-analyses have currently been performed 
only for reporting the incidence of TAVI-related compli- 
cations or identifying predictors of specific adverse events, 
for example, paravalvular leak.
8,9  
However, a comprehen- 
sive analysis of predictors of 30-day and midterm mortality 
is still lacking. The aim of this study was thus to identify 
predictors of post-TAVI 30-day and midterm mortality by 






This study was conducted in accordance with the current 
guidelines, including the recent Preferred Reporting Items for 
Systematic reviews and Meta-Analyses amendment to the Quality 
of Reporting of Meta-analyses statement, and recommendations 
from The Cochrane Collaboration and Meta-analysis Of Obser- 
vational Studies in Epidemiology (MOOSE).
10
 
PubMed and Cochrane databases were searched for reports 
published in English from January 2002 to June 2013 
according to the following highly sensitive strategy, in 
compliance with established methods and incorporating 
wildcards  (identified  by  *):  (TAVI*  OR  TAVR  OR 
independently by 2 reviewers (FG and FDA) at the title and/ 
or  abstract level. The  reports remaining after the  initial 
screening were appraised in the full text with respect to the 
following inclusion criteria: (1) human study, (2) investi- 
gating patients undergoing TAVI, (3) reporting predictors of 
mortality at 30 days or at midterm follow-up, and (4) online 
full-text available publication. All criteria had to be met for 
inclusion. Exclusion criteria were (1) duplicate reporting 
and (2) study population <50 patients. The presence of even 
one of the exclusion criteria sufficed for exclusion. Dupli- 
cate reporting was handled by selecting the study reporting 
on the largest sample of patients undergoing TAVI, or if 
equal, the study with the largest number of overall patients. 
The quality and validity of the included studies were 
independently assessed by 2 reviewers (FG and FDA). After 
modifying the MOOSE item list, to ensure compatibility 
with the included studies, each study was summarized and 
critically appraised with respect to study design, data source, 
the statistical methods used for multivariate analysis, and the 
risk of bias (graded as low, moderate, high, or unknown 
because incomplete reporting may render it impossible to 
ascertain the risk of bias).
10  
Encountered bias was further 
subdivided into analytical, selection, adjudication, detection, 
and attrition bias. 
Relevant study data were extracted independently by the 
reviewers (FG and FDA). The extracted data comprised 
































































































































































































































































































































































































































































































































































































































COPD         GFR <60 
ml/min/m2
 
Thomas17  (2011)                2007e2009         1038             81           576 (56%)            —               146 (14%)         537 (52%)            —                  495 (48%)           236 (23%)      286 (28%)      305 (29%) 
Kempfert18  (2011)              2006e2010           299             82           209 (70%)      115 (52%)        252 (84%)         159 (53%)          8 (3%)                    —                    86 (29%)      129 (43%)        26 (9%) 
Parenica19  (2012)                       —                    29             82             21 (72%)          3 (10%)          26 (90%)               —                   —                         —                      1 (3%)            5 (17%)            — 
Halliday20  (2012)               2008e2010           101          83     1        52 (51%)        22 (22%)               —                      —                   —                         —                         —                   —                   — 
Yong21  (2012)                    2007e2011           119          81     8        72 (61%)        31 (26%)               —                 24 (20%)        22 (18%)             41 (34%)             15 (13%)        40 (34%)            — 
Barbash22  (2012)                2007e2011           165          85     6        96 (58%)        53 (32%)               —                 92 (56%)            —                    81 (49%)             54 (33%)        45 (69%)      128 (78%) 
Sinning23  (2012)                 2009e2010         1315         82     6       765 (58%)      462 (35%)      1166 (89%)         791 (60%)      209 (16%)           693 (53%)           289 (22%)      314 (24%)      786 (60%) 
Buellesfeld24  (2012)           2007e2010           353             83           203 (58%)        92 (26%)        263 (75%)         203 (58%)        61 (17%)           151 (43%)             82 (23%)            —               77 (22%) 
Humphries25  (2012)            2005e2011           641             83           329 (5%1)      197 (31%)        554 (86%)         467 (73%)      259 (40%)           328 (51%)                  —             170 (27%)      413 (64%) 
Tchetche26  (2012)               2010e2011           134          82     5        53 (40%)        30 (22%)        111 (83%)           56 (42%)            —                    56 (42%)             16 (12%)        34 (25%)        37 (28%)                           
Akin27  (2012)                     2007e2008             45          82     7        27 (60%)        17 (38%)          43 (91%)               —                   —                         —                      3 (6%)            8 (2%)          25 (56%) 
Rodes-Cabau28  (2012)        2005e2009           339          81     8      187 (55%)        79 (23%)        308 (90%)         234 (69%)      173 (51%)           215 (63%)           116 (34%)      100 (30%)            —
Latib29  (2012)                     2003e2011           111          81     7        49 (44%)        21 (19%)          75 (67.6%)        44 (40%)        16 (14%) ..                           0                29 (26%)            — Q11
Pilgrim30  (2012)                 2007e2011           389          82     6      224 (58%)      105 (27%)               —               238 (61%)        64 (17%)           166 (43%)             72 (18%)        72 (19%)      268 (69%) 
Hayashida31  (2012)            2006e2011           400          83     6      206 (52%)        92 (23%)        347 (87%)         237 (59%)            —                         —                    63 (16%)      124 (31%)      249 (63%) 
Généreux32  (2013)              2008e2011           218          85     8      106 (48%)        62 (29%)               —                      —                   —                  177 (80%)             89 (40%)        64 (29%)        18 (8%) 
Amabile33  (2013)               2008e2012           173          84     6        91 (53%)        43 (25%)               —               107 (63%)            —                         —                         —               46 (27%)      121 (71%) 
Van der Boon34  (2013)              —                  940          81     7      434 (46%)      268 (29%)        761 (81%)         425 (45%)      158 (17%)           484 (52%)           207 (22%)      323 (34%)      591 (63%) 
Toggweiler35  (2013)           2005e2007             88          87     7        41 (47%)        22 (25%)               —                 63 (72%)        69 (78%)                  —                    34 (39%)        23 (26%)        47 (53%) 
Stortecky36  (2013)              2007e2011           389          83     6      224 (58%)      105 (27%)        255 (66%)         238 (61%)        64 (16%)           166 (43%)             72 (19%)            —             268 (69%) 
Codner37  (2013)                 2008e2012           153          82     6        95 (62%)        45 (29%)        149 (87%)               —               11 (7%)               82 (54%)             38 (25%)        43 (28%)        60 (39%) 
Borz38  (2013)                     2006e2011           250          83     7      135 (54%)        64 (26%)               —                 87 (35%)            —                         —                    49 (20%)            —                   — 
D’Onofrio39  (2013)            2008e2012           774          81     7      446 (58%)      205 (27%)        621 (80%)         168 (22%)        23 (3%)             226 (29%)           167 (33%)      247 (32%)        80 (10%) 
López-Otero40  (2013)         2008e2011             85          83     5        31 (37%)        20 (24%)          70 (82%)             9 (9%)              —                         —                         —               20 (24%)            — 
Seiffert41  (2013)                 2008e2011           326          81     1      181 (56%)            —               266 (82%)         201 (62%)        65 (20%)           180 (55%)             65 (20%)        87 (27%)        29 (9%) 
 
AMI ¼ acute myocardial infarction; CAD ¼ coronary artery disease; COPD ¼ chronic obstructive pulmonary disease; DM ¼ diabetes mellitus; GFR ¼ glomerular filtration rate; NYHA ¼ New York Heart Association. 



















































































































































































































































































































































































































































































































































































Echocardiographic and procedural features 
 










TF                      TA                  TS               TAo                 EDW                   CV              Log ES        STS Score
 
Thomas17  (2011)                     —                  —             257 (25%)               —                 463 (45%)        575 (55%)              0                   0              1038 (100%)               0                    28                  — 
Kempfert18  (2011)              55     13             —                 3 (1%)            81 (27%)                  0                299 (100%)           —                 —               299 (100%)               0               31     16         13     8 
Parenica19  (2012)                     57                  50                    —                 11 (38%)            14 (25%)          15 (26%)             —                 —                 29 (100%)               0                    24                  — 
Halliday20  (2012)                    —                  —                    —                      —                   45 (45%)          56 (55%)              0                   0                      —                       —              22     0.9             — 
Yong21  (2012)                         —             49     16          10 (8%)                 —                 119 (100%)               0                     0                   0                       0                119 (100%)      19     13           6     5 
Barbash22  (2012)                51     15             —                    —                      —                 117 (71%)          48 (29%)              0                  —                     —                       —                   —              12     4 
Sinning23  (2012)                 52     15             —                    —                      —               1143 (87%)        121 (9%)          41 (3%)      10 (1%)                  —                       —              21     14              — 
Buellesfeld24  (2012)                50                  44                    —                 88 (25%)          353 (100%)               0                     0                   0                  34 (10%)        319 (90%)              26                  — 
Humphries25  (2012)                —                  41             166 (26%)               —                 351 (55%)        290 (45%)              0                   0                622 (97%)          19 (3%)                —                   8 
Tchetche26  (2012)               47     13        48     15                0                       —                 125 (93%)                 0                 9 (7%)             0                       0                134 (100%)      24     10              — 
Akin27  (2012)                          48                  57               41 (85%)               —                   45 (100%)              —                   —                 —                 45 (100%)              —                   21                  — 
Rodes-Cabau28  (2012)        55     14             —               27 (8%)            84 (25%)          163 (48%)        176 (52%)              0                   0                339 (100%)               0                    —              10     6 
Latib29  (2012)                     54     13             —                    —                      —                 111 (100%)               0                     0                   0                  70 (63%)          41 (37%)        23     15        4.6     2.3 
Pilgrim30  (2012)                 52     15        44     17               —               111 (31%)          308 (80%)          76 (20%)          5 (1%)             0                164 (42%)        225 (58%)        24     14        6.8     5.3 
Hayashida31  (2012)                 —                  —                    —                      —                        —                       —                   —                 —               347 (87%)          53 (13%)              22                   8 
Généreux32  (2013)              48     16        45     15               —                      —                 140 (64%)          78 (36%)              0                   0                218 (100%)               0                    —              12     5 
Amabile33  (2013)                55     15        49     18               —                      —                 139 (81%)          32 (19%)              0                   0                132 (77%)          39 (23%)        22     12              — 
Van der Boon34  (2013)           —                  —                    —                      —                   79 (84%)          89 (10%)        57 (6%)        4 (0.4%)        435 (46%)        505 (54%)              21                  — 
Toggweiler35  (2013)                60             46     18               —                 17 (19%)            64 (73%)          24 (27%)              0                   0                  88 (100%)               0                    —                   9 
Stortecky36  (2013)              52     15        44     17               —                      —                 308 (79%)          76 (20%)          5 (1%)             0                165 (42%)        224 (58%)        24     14           7     5 
Codner37  (2013)                      —             51     15          52 (33%)               —                 112 (73%)          27 (18%)        13 (9%)        1 (1%)             62 (41%)          91 (60%)        23     13           9     5 
Borz38  (2013)                          —             45     17               —                      —                 190 (76%)          60 (24%)              0                   0                250 (100%)               0               23     13              — 
D’Onofrio39  (2013)             53     13        50     15        173 (22%)          87 (11%)                  0                774 (100%)            0                   0                774 (100%)               0               26     16         10     8 
López-Otero40  (2013)              —                  —                    —                      —                        —                        0                    —                  0                       0                  85 (100%)      29     8                — 
Seiffert41  (2013)                      —             37     2            30 (9%)            48 (19%)          149 (45%)        177 (51%)              0                   0                281 (81%)          45 (13%)        23     2             8     1 
 
CV ¼ CoreValve; EDW ¼ Edwards Sapien; ES ¼ EuroSCORE; LVEF ¼ left ventricular ejection fraction; MR ¼ mitral regurgitation; STS ¼ Society of Thoracic Surgery; TA ¼ transapical; Tao ¼ transaortic; 
TF ¼ transfemoral; TS ¼ trans-subclavian.
























































































Figure 3. Independent predictors of all-cause mortality at midterm follow- 




Meta-regression of baseline features on all-cause death at follow-up 
 
Beta              LCI            UCI            p 
 
Age                                                0.16             0.24           0.32           0.09 
Female gender                               0.001           0.37           0.45           0.90 
Diabetes mellitus                          0.004           0.006         0.004         0.61 
NYHA class more than III            0.01              0.005         0.02           0.04 













Figure 4. Regression of NYHA class >III on logistic event rate. 
 
cases for consistency and discrimination. Any divergence in 
opinion between the reviewers at any stage of the review 
process was resolved by consensus discussion. 
Continuous variables are  reported as  mean      SD  or 
median and range. Categorical variables are expressed as 
counts and percentages. Independent predictors of TAVI- 
related complications and  30-day  and  midterm all-cause 
mortality were appraised and  ordered according to  their 
measure of risk (either OR or hazard ratio) with Review 
Manager (RevMan), version 5.2,  freeware package (The 
Cochrane  Collaboration,  The  Nordic  Cochrane  Center, 
Copenhagen, Denmark) and Comprehensive Meta-Analysis. 
Small study bias was appraised by graphical inspection of 
funnel plots. Hypothesis testing for superiority was set at the 
2-tailed 0.05 level. Hypothesis testing for statistical homo- 
geneity was set at the 2-tailed 0.10 level and based on the 
Cochran Q test, with I
2   
values of 25%, 50%, and 75% 






The search strategy yielded 1,088 reports. Four reports 
derived from congresses were added, resulting in a total of 
1,092 citations. All citations were first screened at title and 
abstract level; the 31 remaining reports were subsequently 
screened full text. Of the full-text analyzed citations, 4 were 
excluded because of reporting duplicate data
11e14   
and 2 











































529 COPD 0.06 0.08           0.10           0.75 adverse   events.





0.12           0.88
 




















0.10             0.01 
 
COPD ¼ chronic obstructive pulmonary disease; LCI ¼ low confidence 




the study group, baseline patient characteristics, procedural 
features, and multivariate predictors of all-cause mortality 
(estimator, point summary estimate of risk, 95% confidence 
intervals [CIs]). End points of interest for the present review 
were  the  incidence  of  TAVI-related  complications  and 
30-day and midterm all-cause mortality. Multivariate pre- 
dictors with an odds ratio (OR) >5 reported in at least 3 
studies were reported. Meta-regression analysis was per- 
formed for midterm all-cause mortality for baseline clinical 
variables. 
Result analysis of the studies was registered on dedicated 
electronic forms. The forms were piloted over the first 5 
 
The 25 included studies reported on a total of 8,874 
patients treated with TAVI for symptomatic severe aortic 
stenosis (AS). Approximately 1/2 of the patients were 
women (54.6%); median age was 82.5     1.5 years. Mean 
logistic EuroSCORE-I was 23.4     3.1% and was above 
20% in all studies, except for one (19     13%).
21  
In those 
studies (n ¼ 5) in which reporting results was exclusively 
done using     the     Society     of     Thoracic     Surgery 
score,
22,25,28,32,35  
the mean risk of perioperative mortality 
was  >5%.  Diabetes mellitus was  present in  24%  (n  ¼ 
2,153) of patients, renal insufficiency in 48% (n ¼ 4,264), 
and a history of previous revascularization (either surgical or 
percutaneous) in 40% (n ¼ 3,541). Left ventricular ejection 
fraction (LVEF) was  in  general preserved, except for 3 
studies in  which  mean  LVEF  was  mildly compromised 
(range of mean LVEF 47% to 60%).
26,27,32 
The most 













































































A small majority of patients were treated by the trans- 
femoral approach (51.1%), followed by the transapical 
approach (33.7%), and only few patients received a direct 
aortic or trans-subclavian procedure (1.5% and 0.2%, 
respectively). In 60.8% (n ¼ 5,392) of patients, an Edwards 
SAPIEN or SAPIEN XT balloon-expandable valve (both 
Edwards Lifesciences, Irvine, California) was implanted, 
and in 21.4% (n ¼ 1,899) of patients, the self-expandable 
third-generation Medtronic CoreValve (Medtronic Inc., 
Minneapolis, Minnesota) prostheses were used, whereas 3 
studies (comprising 15.8% of patients, n ¼ 1,583) did not 
specify the type of valve implanted.
20,22,23  
Because of the 
infrequent reporting of  conversion to  surgery and  intra- 
procedural death, no reliable incidence could be reported for 
these events. Table 2 summarizes procedural TAVI char- 
acteristics in the various studies. 
At 30 days, 7.5% (n ¼  663) of patients died. Acute 
kidney injury (AKI) occurred in 8.02% (n ¼  712), life- 
threatening and  major  bleeding  in  13.8%  (n  ¼  1,224), 
major  vascular complications in  8.8%  (n  ¼  782),  peri- 
procedural acute myocardial infarction (AMI) in 0.6% (n ¼ 
51), and pacemaker implantation in 12.5% (n ¼ 1,106) of 
patients. At midterm follow-up (median 365 days, inter- 
quartile range 267 to 365), 21.6% (n ¼ 1,917) of patients 
had died. The strongest predictors of 30-day mortality were 
AKI stage    2 (OR 18.0, 95% CI 6.25 to 52), preprocedural 
hospitalization for at least 1 week (OR 9.36, 95% CI 2.55 to 
35), periprocedural AMI (OR 8.54, 95% CI 2.57 to 33.52), 
and preprocedural increased proebrain natriuretic peptide 
(pro-BNP) levels (OR 5.35, 95% CI 1.74 to 16.5; Figure 2). 
The  most  important  predictors  for  cumulative  midterm 
mortality were increased pro-BNP levels (OR 11, 95% CI 
1.51 to 81), AKI stage 3 (OR 6.80, 95% CI 2.55 to 15.66), 
LVEF  <30%   (OR  6.67,  95%  CI  3.5  to  12.76),  and 
periprocedural AMI  (OR  6.52,  95%  CI  2.34  to  18.14; 
Figure 3). 
At meta-regression analysis, similarly, NYHA class >III was 





Profound understanding of factors determining patient 
survival after TAVI is of paramount importance in clinical 
practice not only to enable to accurately select patients, that 
is, only those in whom treatment benefit outweighs the risk, 
but also to take appropriate measures to prevent complica- 
tions in high-risk subjects, especially considering that the 
commonly used logistic EuroSCORE falls short in predict- 
ing mortality, as it does not take account of periprocedural 




This is the largest systematic review to assess predictors 
Based on Valvular Academic Research Consortium 1 
criteria, the strongest predictor for 30-day mortality was 
stage    2  AKI, whereas stage 3  AKI  was  an  important 
determinant of midterm mortality. The reported incidence of 
AKI after percutaneous valve implantation varies from 8% 
to 28%,
32,44e47  
mainly because of differences in AKI defi- 
nition, which is considerably lower than that observed after 
cardiac surgery.
48   
Many patients actually demonstrate an 
improvement of renal function after TAVI rather than kid- 
ney injury, as abolishment of the valvular obstruction leads 
to improved renal hemodynamics.
44 
Several factors are 
believed to be involved in the undesired development of 
AKI. Intraprocedural episodes of hypotension and emboli 
generated by catheter manipulations, balloon valvuloplasty 
and/or prosthesis deployment, and postprocedural bleedings 
might result in tubular ischemia and consequential decrease 
in kidney function.
46,47   
Moreover, the occurrence of para- 
valvular aortic regurgitation produces acute volume over- 
load   with   a   subsequent   increase   in   left   ventricular 
end-diastolic pressure, ultimately leading to a reduction in 
diastolic renal blood flow and impairment of renal func- 
tion.
46  
The fact that AKI is most strongly associated with 
short-term mortality,  also  shown  in  the  present  review, 
supports this hypothesis. 
Preprocedural   elevated   pro-BNP   levels   (measured 
24  hours before TAVI) were also  a  strong independent 
predictor of both 30-day and midterm mortality. The prog- 
nostic value of natriuretic peptides was previously recog- 
nized in interventions on the aortic valve.
49,50    
Likewise, 
baseline BNP and pro-BNP levels have been identified as 
independent predictors of 30-day and long-term mortality in 
TAVI, respectively.
49e52  
The unfavorable outcome of valve 
interventions in patients with high BNP levels is believed to 
be related to the presence of impaired systolic and/or dia- 
stolic left ventricular function, as both types of myocardial 
dysfunction  are  associated  with  elevated  BNP  levels.
49
 
Patients with high preprocedural BNP might benefit from 
optimization of their hemodynamic status by bridging 
therapy (optimization of medical therapy or balloon valvu- 
loplasty) before proceeding to TAVI, although further 
research is warranted to confirm this. 
Not surprisingly, preprocedural hospitalization (mainly 
for decompensated AS) and  preprocedural LVEF    30% 
were among the strongest predictors of 30-day and midterm 
mortality, respectively. This finding reflects, on one hand, 
the severity of AS disease and, on the other hand, a poorer 
functional  status,  characterizing the  more  frail  patients. 
Moreover, recent research revealed that clinically inoperable 
patients, a designation often based on frailty, have worse 
survival compared with technically inoperable patients.
52
 
Finally, periprocedural myocardial injury and infarction 






























































highly symptomatic patients with severe AS from all over 
the world, undergoing TAVI treatment from 2003 to 2012, 
and thus represents a wide range of TAVI experience. The 
30-day and midterm mortality rates in this large group of 
patients were 7.5% and 21.6%, respectively, signifying that 
nearly 30% of deaths occurred within the first 30 days after 
TAVI, well in line with data previously reported by several 
real-world registries and 1 meta-analysis.
42,43
 
myocardial injury, as an increase in the troponin level above 
the URL is observed in nearly all patients.
21,53,54  
A single 
study demonstrated a strong association between biomarker- 
determined myocardial injury (defined as peak values of 
cardiac troponin T and/or creatine kinase-MB >5 times the 
URL, not fulfilling the criteria for myocardial infarction) 
and 30-day and 1-year survival rates.
54  
Myocardial injury 



























ischemia, resulting from a mismatch in myocardial oxygen 
supply and demand. The diffuse nature of myocardial injury 
makes it unlikely to cause left ventricular dysfunction with 
subsequent heart failure or myocardial scarring prone to 
ventricular arrhythmia. Therefore, it was hypothesized that 
myocardial injury is a marker for more extensive (vascular) 
disease, which may  increase the  risk  for  postprocedural 
adverse events.
21  
Periprocedural myocardial infarction, 
defined by the additional development of new Q waves and/ 
or  wall  motion  abnormalities according to  the  Valvular 
Academic Research Consortium criteria, is a rare finding 
estimated   to   occur   in   approximately   1%   of   TAVI 
cases.
21,53e55  
In this review, it was identified as one of the
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strongest predictors of midterm mortality. 
There was a great deal of overlap between the strongest 
predictors of 30-day and cumulative midterm mortality in 
the present work. This might origin from true shared pre- 
dictors of both events, or it might reflect an overwhelming 
effect of 30-day mortality on the analysis of predictors for 
cumulative midterm death rates. The most powerful pre- 
procedural predictors (elevated BNP, preprocedural hospi- 
talization, and reduced LVEF) of mortality were 
predominantly related to AS disease severity, suggesting 
that timely reference for TAVI might be vital to increase the 
odds of postprocedural survival. All the postprocedural 
predictors (AKI and AMI) were associated with TAVI 




In this systematic review, the strongest independent pre- 
dictors of 30-day and cumulative midterm mortality were 
identified by means of their measured effect size (expressed 
by their OR or hazard ratio). The reporting of predictors was 
therefore entirely determined by an arbitrarily set OR 
threshold of 5.0, meaning that less-influential predictors were 
not presented. These include predictors that might be of 
clinical importance based on their prevalence in the popula- 
tion with TAVI, rather than their effect size. The results of 
this study should be interpreted in the light of this notion. 
Furthermore, the  literature referred to  in  this  review 
represents a considerable range of TAVI experience, insti- 
tutional  routines,  follow-up  durations,  and  complication 
definitions. The present analysis did not take into account 
this heterogeneity of the included studies, potentially 
hampering the generalizability of the results. Moreover, the 
validity of the multivariate analyses that yielded the inde- 
pendent predictors heavily depends on whether all potential 
predictors were measured and included in the model, as 
multivariate analysis does not consider unmeasured vari- 
ables. Finally, the present review is a not patient lev- 
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